Santen Pharmaceutical Co. and Asahi Glass Co. have fended off U.S. Patent Trial and Appeal Board challenge filed by Micro Labs Limited over the validity of a patent for glaucoma and ocular hypertension treatment.
Micro Labs failed to prove that U.S. Patent 5,886,035 for the basic compound on the drug, was invalid, the administrative review board ruled Nov. 28.
Micro Labs had filed the challenge after Santen, Asahi Glass and Akorn’s Oak Pharmaceuticals had sued to block generic version of Zioptran.
Micro Labs and the patent owners had sought to drop the challenge on Nov. 27. The board dismissed Micro...